UroGen Pharma Ltd.
NASDAQ:URGN
Overview | Financials
Company Name | UroGen Pharma Ltd. |
Symbol | URGN |
Currency | USD |
Price | 11.08 |
Market Cap | 467,569,352 |
Dividend Yield | 0% |
52-week-range | 10.26 - 20.7 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Elizabeth A. Barrett |
Website | https://www.urogen.com |
An error occurred while fetching data.
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD